Swedish biotech companies have a broad and varied product pipeline that is attracting attention from venture capitalists and pharmaceutical companies.
News|Articles|May 6, 2019
Event Addresses Biotech Startup Challenges
Author(s)Pharmaceutical Technology Editors
MilliporeSigma event scheduled to recognize biotech challenges and support development potential.
Advertisement
The challenges biotech companies face when developing and launching new therapies, including process development, manufacturing, and regulatory compliance, while balancing resource and financial constraints, will be the focus of a Biotech Startup Summit hosted by MilliporeSigma on May 16, 2019, at the company’s Cambridge Innovation Center in Boston, MA.
The event, “Advancing Molecules to Market-Is Yours Next?”, will include presentations by three finalists for MilliporeSigma’s 6th Advance Biotech Grant Program in North America. The grant program provides process solution products and services and/or process development support to biotech companies with molecules in development.
The 2019 North America grant finalists, as reported by MilliporeSigma, include:
- Raft Pharmaceuticals, for an approach to treat chronic pain using a biologic to selectively inhibit neuroinflammation without affecting normal motor or sensory function.
- TechnoVax, for developing a virus-like particle platform that facilitates the development and production of a range of vaccines targeting the prevention of respiratory diseases, as well as hemorrhagic fevers, immunodeficiency, and cancers.
- Rubicon Biotechnology, for developing a therapeutic protein, Fv-Hsp72, designed to protect and salvage cells damaged from an acute event, such as traumatic brain injury.
The program also will feature a panel discussion on strategies for advancing molecules to market; topics include early stage funding, process development, tech transfer, new trends and therapies, FDA regulations, and the transition from a scientist to an entrepreneur. An expert panel from different sectors of the biotech community will participate in the discussion. The panelists are Mukesh Kumar, regulatory consultant and CEO, FDAMap.com; Johannes Fruehauf, president and CEO of Biolabs, executive director of LabCentral, and general partner of BioInnovation Capital; Sébastien Ribault, senior director, MilliporeSigma Global BioReliance, End to End Solutions; Jean Bender, vice president and principal consultant at Visterra; and Tom Ransohoff, managing director, BPTC Group, BDO. Rita Peters, editorial director of BioPharm International, will moderate the panel discussion.
Source:
Advertisement
Related to this article
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Advertisement
Advertisement